Based on the data at the interim analysis of Feb 25, 2021, it is estimated that the chance for success, that the survival benefit of ADI PEG-20 over the control group is statistically significant at the end of the trial, will be greater than 80%. The independent Committee conducted the interim analysis recommended that the Phase III clinical trial continue according to the protocol, without the need to increase sample size.